Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC StudyZacks Investment Research • 06/09/26
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash BidInvestors Business Daily • 06/09/26
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's whyInvezz • 06/09/26
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound downMarket Watch • 06/09/26
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FTCNBC • 06/09/26
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis RegressionGlobeNewsWire • 06/08/26
US bank sees GSK oncology pipeline as major value driver after New York conferenceProactive Investors • 06/04/26
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/03/26
GSK Bets on Specialty Medicines to Drive Long-Term Revenue GrowthZacks Investment Research • 06/03/26
UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment dragsProactive Investors • 06/03/26
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgradingProactive Investors • 05/29/26
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment TranscriptSeeking Alpha • 05/28/26
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studiesReuters • 05/28/26